Goette, Andreas
Eckardt, Lars
Valgimigli, Marco
Lewalter, Thorsten
Laeis, Petra
Reimitz, Paul-Egbert
Smolnik, Rüdiger
Zierhut, Wolfgang
Tijssen, Jan G.
Vranckx, Pascal
Funding for this research was provided by:
Daiichi Sankyo Foundation of Life Science
Universitätsklinikum Magdeburg
Article History
Received: 20 August 2020
Accepted: 7 October 2020
First Online: 24 October 2020
Change Date: 18 November 2020
Change Type: Update
Change Details: “Age, history of CHF, and AF type”, third paragraph, the first sentence has been corrected and now reads: There was no interaction of AF type for major or CRNM bleeding and composite efficacy (Figs. 3a and 3b).
Compliance with ethical standards
:
: Andreas Goette discloses honoraria and speaker fees from Astra Zeneca, Bayer Health Care, Berlin-Chemie, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Medtronic, Novartis, and Omeicos. Research has been supported by Josef-Freitag Stiftung and Deutsche Herzstiftung e.V. outside the submitted work. Thorsten Lewalter reports personal fees from Abbott, Boston Scientific, Bayer, Boehringer, Daiichi Sankyo, and Pfizer outside the submitted work. Marco Valgimigli reports grants and personal fees from Abbott, Alvimedica, Amgen, Bayer, Bristol-Myers Squibb SA, Coreflow, Daiichi Sankyo, Vifor, Idorsia, Terumo, and iVascular; grants and personal fees from grants from AstraZeneca and Medicure, outside the submitted work. Lars Eckardt discloses consultant fees, speaking honoraria, and travel expenses from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boehringer, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi Aventis. Research has been supported by German Research Foundation (DFG) and German Heart Foundation outside the submitted work. Petra Laeis, Paul-Egbert Reimitz, Rüdiger Smolnik and Wolfgang Zierhut are employees of Daiichi Sankyo Europe GmbH, Munich, Germany. Jan G. Tijssen reports personal fees from AstraZeneca, Bayer, and Boehringer Ingelheim outside the submitted work. Pascal Vranckx discloses personal fees from Daiichi Sankyo during the conduct of the study; and personal fees from AstraZeneca, Bayer Health Care, CLS Behring, and Terumo outside the submitted work.
: The final study protocol and informed consent form were reviewed and approved by the ethics boards/institutional review boards and corresponding health authorities for all participating study sites.
: Written informed consent was obtained from patients for inclusion in this study.